ADHD
Shire posts strong quarter results
August 2, 2012Sales and Marketing ADHD, Adderall XR, Pfizer, Q2, Shire, results
Shire has posted a set of healthy financials for the second quarter, buoyed by its ADHD and rare drug portfolio. …
Generic approval for Shire’s hyperactivity drug
June 26, 2012Sales and Marketing ADHD, Adderall XR, FDA, IMS Health, Impax, Shire, Teva
US regulators have delivered a blow to Shire by allowing Actavis Group to produce a generic version of its hyperactivity …
Shire sales rocket with 25% growth
July 29, 2011Sales and Marketing ADHD, Fabry disease, Gaucher's disease, Shire
Specialist pharma company Shire has posted exceptionally strong results for the second quarter, increasing its product sales by 30% and …
Shire thrives on specialist portfolio
February 11, 2011Sales and Marketing 2010 pharma results, ADHD, Shire, Vyvanse
Speciality pharma company Shire has posted sales growth of 16%, led by its ADHD treatment Vyvanse. Sales of Vyvanse rose …
Digital Pharma: Janssen gets animated about ADHD
June 14, 2010Medical Communications, Sales and Marketing ADHD, Janssen, disease awareness campaigns
Janssen-Cilag has launched a new UK campaign to raise awareness of ADHD among teenagers, their parents and teachers. The campaign’s …
AstraZeneca’s AZD3480 progresses in ADHD
July 11, 2009Sales and Marketing ADHD, Alzheimer's, Alzheimer's ADHD, AstraZeneca
AstraZeneca is to progress its AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million …
Shire acquires ADHD presence in Europe
February 23, 2009Sales and Marketing ADHD, Shire
Shire has bought the global rights for two established treatments for Attention Deficit Hyperactivity Disorder from UCB. The acquisition gives …
Latest content
